Results 101 to 110 of about 113,823 (359)

Hemophilia treatment and transfusion medicine

Zhongguo shuxue zazhi
The improvement of hemophilia treatment is attributed to the development of transfusion medicine, and the discovery of cryoprecipitate has opened up a new era of hemophilia treatment, laying the foundation for the development of modern hemophilia ...
FANG Yunhai, CHENG Yan, ZHANG Xinsheng
doaj   +1 more source

Antithrombin: Deficiency, Diversity, and the Future of Diagnostics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable.
Mirjam Kruijt, Christa M. Cobbaert, L. Renee Ruhaak   +2 more
wiley   +1 more source

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

TH Open, 2019
Introduction Optimizing hemophilia care remains challenging in developing countries. Burden-of-disease studies are important to develop strategies for improving hemophilia care.
Naresh Gupta, Abderrahmane Benbouzid, Meriem Belhani, Mohammed El Andaloussi, Khadija Maani, Yasser Wali, Soraya Benchikh El Fegoun, Hossam Ali Saad, Johnny Mahlangu   +8 more
doaj   +1 more source

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

Research and Practice in Thrombosis and Haemostasis, 2020
Background Hemophilia gene therapy is a rapidly evolving therapeutic approach in which a number of programs are approaching clinical development completion.
Flora Peyvandi, David Lillicrap, Johnny Mahlangu, Claire McLintock, K. John Pasi, Steven W. Pipe, Wendy Scales, Alok Srivastava, Thierry VandenDriessche   +8 more
doaj   +1 more source

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston, Derom, Eric, Petrovic, Mirko   +2 more
core  

Randomized trial of a DVD intervention to improve readiness to self-manage joint pain [PDF]

, 2011
Report of a randomized controlled trial of a motivational intervention to promote self-management of joint painA DVD (digital video disk) intervention to increase readiness to self-manage joint pain secondary to hemophilia was informed by a 2-phase ...
Abraham, Altman, Angst, Barlow, Barlow, Barry, Biller, Bode, Carr, Choiniere, Dijkstra, Elander, Elander, Elander, Fischer, Glenn, Habib, Hadjistavropoulos, Hays, Hays, Heapy, Jensen, Jensen, Jensen, Jensen, Kazis, Kerns, Kerns, Kerns, LeFort, Liao, Luck, McCracken, Moore, Nielsen, Prochaska, Richmond, Ruta, Szende, Turk, Turk, Von Korff, Vowles, Warsi   +43 more
core   +2 more sources

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction [PDF]

, 2022
Junjiang Sun, Xiaojing Chen, Zheng Chai, Hongqian Niu, Amanda L. Dobbins, Timothy C. Nichols, Chengwen Li   +6 more
openalex   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort

Research and Practice in Thrombosis and Haemostasis, 2022
Background Gene therapy shows promise as a potential “cure” for hemophilia A and B. Adeno‐associated virus (AAV) vectors are the leading platform to deliver modified genetic code of factor VIII or IX to the liver effecting endogenous production.
Sara Boyce, Izabela James, Savita Rangarajan, Nicola Curry, Catherine Bagot, Steven Austin, Mike Laffan, Sarah Mangles, Kandiah Chandrakumaran, Carina Mundy   +9 more
doaj   +1 more source